4.8 Article

A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses

期刊

LANCET
卷 376, 期 9750, 页码 1393-1400

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61267-6

关键词

-

资金

  1. Merck
  2. Daiichi Sankyo
  3. Alnylam
  4. Pfizer
  5. Wellcome Trust [WT089062/Z/097Z, WT089061/Z/09/Z]
  6. US National Institutes of Health [R01 HL087676]
  7. Donovan Family Foundation
  8. Center of Excellence for Complex Disease Genetics of the Academy of Finland [213506, 129680]
  9. Biocentrum Helsinki Foundation
  10. Nordic Center of Excellence in Disease Genetics
  11. Academy of Finland [129494]
  12. Finnish Foundation for Cardiovascular Research
  13. Sigrid Juselius Foundation
  14. Finnish Academy [129322]
  15. Academy of Finland (AKA) [129322] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

Background Comparison of patients with coronary heart disease and controls in genome-wide association studies has revealed several single nucleotide polymorphisms (SNPs) associated with coronary heart disease. We aimed to establish the external validity of these findings and to obtain more precise risk estimates using a prospective cohort design. Methods We tested 13 recently discovered SNPs for association with coronary heart disease in a case-control design including participants differing from those in the discovery samples (3829 participants with prevalent coronary heart disease and 48 897 controls free of the disease) and a prospective cohort design including 30 725 participants free of cardiovascular disease from Finland and Sweden. We modelled the 13 SNPs as a multilocus genetic risk score and used Cox proportional hazards models to estimate the association of genetic risk score with incident coronary heart disease. For case-control analyses we analysed associations between individual SNPs and quintiles of genetic risk score using logistic regression. Findings In prospective cohort analyses, 1264 participants had a first coronary heart disease event during a median 10.7 years' follow-up (IQR 6.7-13.6). Genetic risk score was associated with a first coronary heart disease event. When compared with the bottom quintile of genetic risk score, participants in the top quintile were at 1.66-times increased risk of coronary heart disease in a model adjusting for traditional risk factors (95% CI 1.35-2.04, p value for linear trend=7.3x10(-10)). Adjustment for family history did not change these estimates. Genetic risk score did not improve C index over traditional risk factors and family history (p=0.19), nor did it have a significant effect on net reclassification improvement (2.2%, p=0.18); however, it did have a small effect on integrated discrimination index (0.004, p=0.0006). Results of the case-control analyses were similar to those of the prospective cohort analyses. Interpretation Using a genetic risk score based on 13 SNPs associated with coronary heart disease, we can identify the 20% of individuals of European ancestry who are at roughly 70% increased risk of a first coronary heart disease event. The potential clinical use of this panel of SNPs remains to be defined.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据